Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1586711 | 0.92 | CASP3 (0.49) | CASP3ACHEKMT2ANPSR1RXFP1 | |
| SCHEMBL20765935 | 0.92 | KMT2A (0.46) | CASP3ACHEKMT2ANPSR1ADORA1 | |
| SCHEMBL6304400 | 0.91 | ACHE (0.49) | CASP3ACHEGPR119MAPK1STS | |
| SCHEMBL17629577 | 0.88 | MAPT (0.42) | CASP3KMT2ANPSR1ADORA1ADORA3 | |
| SCHEMBL1219803 | 0.82 | ADORA1 (0.43) | KMT2AADORA1MEN1GPR119 | |
| SCHEMBL21047249 | 0.82 | ADORA1 (0.43) | KMT2AADORA1MEN1GPR119 | |
| SCHEMBL435995 | 0.82 | ADORA1 (0.43) | CASP3KMT2AADORA1ADORA3PDE4D | |
| SCHEMBL1219800 | 0.82 | ADORA1 (0.43) | KMT2AADORA1MEN1GPR119 | |
| SCHEMBL13488441 | 0.82 | CXCR3 (0.43) | KMT2ANPSR1ADORA1MEN1SMN1; SMN2 | |
| SCHEMBL13488374 | 0.81 | ALDH1A1 (0.49) | KMT2ANPSR1ADORA1MEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3833672-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | Ospedale San Raffaele S.r.l. (IT) | 2021-06-16 | — | — | EP | disclosed |
| WO-2021018238-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-02-04 | — | — | WO | disclosed |
| WO-2020030781-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020030781-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-02-13 | — | — | WO | disclosed |
| EP-1578743-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2006-11-29 | — | — | EP | disclosed |
| EP-1719770-A2 | Quinoline derivatives as antibacterials | SMITHKLINE BEECHAM PLC (GB) | 2006-11-08 | — | — | EP | disclosed |
| EP-1320529-B1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2006-05-24 | — | — | EP | disclosed |
| US-20060041123-A1 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| US-6989447-B2 | Compounds | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-01-24 | — | — | US | disclosed |
| EP-1121355-B1 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1202987-B1 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-11-26 | — | — | EP | disclosed |
| US-6602882-B1 | Quinoline derivatives and their use as antibacterial agents | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-08-05 | — | — | US | disclosed |
| EP-1320529-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-25 | — | — | EP | disclosed |
| EP-1202987-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2002024684-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-28 | — | — | WO | disclosed |
| EP-1144404-A1 | PIPERIDINYLQUINOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2001-10-17 | — | — | EP | disclosed |
| EP-1121355-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2001-08-08 | — | — | EP | disclosed |
| WO-2001007433-A2 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-02-01 | — | — | WO | disclosed |
| WO-2000043383-A1 | PIPERIDINYLQUINOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000021952-A1 | QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041123-A1 | Antibacterial agents | NQO2, NRDC, IFNG | CASP3 335/4885ACHE 2793/4885KMT2A 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.